Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207425 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03207425 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT03207425, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.
Interventions
- DRUG EDP 305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2017-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207425
The ClinicalTrials.gov registry entry for NCT03207425 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDP 305 is the first listed.
NCT03207425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207425 about?
NCT03207425 is a clinical study titled "A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers". This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.
What is the current status of trial NCT03207425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-06-14. Estimated completion is 2017-09-19.
What interventions are being tested in trial NCT03207425?
The interventions under investigation include: EDP 305 (DRUG).
Who is sponsoring clinical trial NCT03207425?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.